Top

Journal of Radiation Oncology

Published in:

01-12-2014 | Original Research

Adoption of Radiation Therapy Oncology Group consensus guidelines for post-prostatectomy radiation therapy in an academic tertiary care center

Authors: David M. Marcus, Peter J. Rossi, Sherrie Cooper, Ashesh B. Jani

Published in: Journal of Radiation Oncology | Issue 4/2014

Abstract

Objective

This study aimed to define the impact of Radiation Therapy Oncology Group (RTOG) guidelines for clinical target volume (CTV) delineation for post-prostatectomy external beam radiation therapy (EBRT) on radiation dosimetry and toxicity.

Methods

We reviewed the records of 125 patients treated with post-prostatectomy EBRT at our institution. We recorded CTV size, dosimetric parameters for the rectum and bladder, and acute and late gastrointestinal (GI) and genitourinary (GU) toxicity. To estimate the impact of the RTOG guidelines, patients treated prior to 2010 were compared to patients treated from 2010 to 2013 for each of these endpoints.

Results

CTVs were larger and less variable for patients treated from 2010 to 2013 (mean 143.6 cm³, standard deviation (SD) 43.9) compared to patients treated prior to 2010 (mean 88.9 cm³, SD 65.6) (p < 0.001). Although patients treated from 2010 to 2013 had higher bladder volume receiving 65 Gy (V65) (47.7 vs. 32.9 %, p = 0.03), V50 (58.3 vs. 45.4 %, p = 0.04), V30 (81.9 vs. 61.9 %, p = 0.03), V20 (94.3 vs. 80.8 %, p = 0.01), and V10 (97.9 vs. 90.0 %, p = 0.05), there were no differences in acute (p = 0.17) or late (p = 0.59) GU toxicity between groups. There were no differences in acute (p = 0.22) or late (p = 0.40) GI toxicity between groups.

Conclusion

Adoption of RTOG guidelines for post-prostatectomy EBRT was associated with larger and less variable CTVs at our institution. There have been no changes in treatment-related toxicity compared to patients treated prior to publication of the guidelines.

Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30. doi:10.3322/caac.21166 PubMedCrossRef

Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H (2000) Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 164(1):101–105PubMedCrossRef

Bianco FJ Jr, Scardino PT, Eastham JA (2005) Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (“trifecta”). Urology 66(5 Suppl):83–94. doi:10.1016/j.urology.2005.06.116 PubMedCrossRef

Han M, Partin AW, Pound CR, Epstein JI, Walsh PC (2001) Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin N Am 28(3):555–565CrossRef

Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, Klein EA, Kupelian PA, Roehrborn CG, Pistenmaa DA, Pacholke HD, Liauw SL, Katz MS, Leibel SA, Scardino PT, Slawin KM (2004) Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. J Am Med Assoc 291(11):1325–1332. doi:10.1001/jama.291.11.1325 CrossRef

Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC (2008) Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. J Am Med Assoc 299(23):2760–2769. doi:10.1001/jama.299.23.2760 CrossRef

Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Colombel M, van de Beek C, Verhagen P, van den Bergh A, Sternberg C, Gasser T, van Tienhoven G, Scalliet P, Haustermans K, Collette L, European Organisation for Research and Treatment of Cancer Radiation Oncology and Genito-Urinary Groups (2012) Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 380(9858):2018–2027. doi:10.1016/S0140-6736(12)61253-7 PubMedCrossRef

Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181(3):956–962. doi:10.1016/j.juro.2008.11.032 PubMedCentralPubMedCrossRef

Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Storkel S, Willich N, Semjonow A, Souchon R, Stockle M, Rube C, Weissbach L, Althaus P, Rebmann U, Kalble T, Feldmann HJ, Wirth M, Hinke A, Hinkelbein W, Miller K (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol Off J Am Soc Clin Oncol 27(18):2924–2930. doi:10.1200/JCO.2008.18.9563 CrossRef

10.

Michalski JM, Lawton C, El Naqa I, Ritter M, O’Meara E, Seider MJ, Lee WR, Rosenthal SA, Pisansky T, Catton C, Valicenti RK, Zietman AL, Bosch WR, Sandler H, Buyyounouski MK, Menard C (2010) Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 76(2):361–368. doi:10.1016/j.ijrobp.2009.02.006 PubMedCentralPubMedCrossRef

11.

Cozzarini C, Fiorino C, Ceresoli GL, Cattaneo GM, Bolognesi A, Calandrino R, Villa E (2003) Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6–70.2 Gy). Int J Radiat Oncol Biol Phys 55(3):688–694PubMedCrossRef

12.

Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO (2010) Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys 76(3 Suppl):S123–S129. doi:10.1016/j.ijrobp.2009.03.078 PubMedCentralPubMedCrossRef

13.

Pinkawa M, Fischedick K, Asadpour B, Gagel B, Piroth MD, Eble MJ (2006) Low-grade toxicity after conformal radiation therapy for prostate cancer—impact of bladder volume. Int J Radiat Oncol Biol Phys 64(3):835–841. doi:10.1016/j.ijrobp.2005.09.003 PubMedCrossRef

14.

Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21(1):109–122PubMedCrossRef

15.

Pederson AW, Fricano J, Correa D, Pelizzari CA, Liauw SL (2012) Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity. Int J Radiat Oncol Biol Phys 82(1):235–241. doi:10.1016/j.ijrobp.2010.09.058 PubMedCrossRef

16.

Cheng JC, Schultheiss TE, Nguyen KH, Wong JY (2008) Acute toxicity in definitive versus postprostatectomy image-guided radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 71(2):351–357. doi:10.1016/j.ijrobp.2007.09.043 PubMedCrossRef

Title: Adoption of Radiation Therapy Oncology Group consensus guidelines for post-prostatectomy radiation therapy in an academic tertiary care center
Authors: David M. Marcus
Peter J. Rossi
Sherrie Cooper
Ashesh B. Jani
Publication date: 01-12-2014
Publisher: Springer Berlin Heidelberg
Published in: Journal of Radiation Oncology / Issue 4/2014
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI: https://doi.org/10.1007/s13566-014-0172-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2014

Prognostic utility of serial PET/CT imaging following stereotactic body radiation therapy (SBRT) in early stage lung cancer: a single institution experience

Efficacy of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to the prostate for intermediate- and high-risk prostate cancer

Stereotactic body radiotherapy (SBRT)/stereotactic ablative body radiotherapy (SABR) for “radioresistant” renal cell carcinoma (RCC)

103Pd versus 125I ophthalmic plaque brachytherapy: preoperative comparative radiation dosimetry for 319 uveal melanomas

A phase II study of surgical excision, temozolomide, radiotherapy, and anti-EGFR radioimmunotherapy (EXTRA) as adjuvant therapy in high-grade gliomas

Treatment of maxillary sinus cancer in the modern era: one institution’s experience

Keynote webinar | Spotlight on antibody–drug conjugates in cancer